癌症患者并非死于癌症本身，而是死于消瘦和可的松（激素紊乱）。
原始表述
كل عانين السرطان ما بيموتو بسرطان اصلا بيموتوا بايه بكشكش يا هزال الكورتيزون
按来源为原话. 译文由本项目提供；以阿拉伯语原文为准。
译文
癌症患者并非死于癌症本身，而是死于消瘦和可的松（激素紊乱）。
出处
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- السرطان ١ (打开来源)
- 发布日期
- 2025年1月26日
- 时间戳
- 0:44:54 (在原视频 YouTube 自动字幕轨中的位置；可确认该内容出现的位置，但不能确认说话人是谁)
- 归属的不确定性
- Archive transcript (YouTube CC or AI-generated); no timestamps; spelling errors of the machine transcript are kept verbatim; wording may deviate from the spoken words.
- 涉及人群
Patients with advanced cancer
- Elawady 设定的地域限制
none found
科学评估
基本错误 – 该说法的主要部分没有证据支持，或被严重夸大。
证据确定性: 中 – 进一步研究仍可能影响该评估。
1. 说法是什么？
Death is due to wasting/cortisone, not cancer.
2. 哪些内容可证实是正确的？
Cachexia (wasting) is a frequent, serious feature of advanced cancer and can be a proximal cause of death, for example through loss of heart or breathing muscle (I-CAN-108). Glucocorticoid signalling contributes to tumour-induced muscle wasting in mice (I-CAN-109), and prolonged corticosteroid medication causes rapid muscle loss in cachectic patients (I-SRC-108).
3. 哪些内容是错误或夸大的？
Cachexia is driven by the tumour (cytokines, reduced intake, metabolic changes) and is not fully reversible by nutrition (I-CAN-06, I-CAN-108); it often improves when anticancer treatment is effective (I-SRC-108). It is therefore part of dying from cancer, not an alternative to it. In a hospital series the underlying cause of death was cancer-related in 83% (I-CAN-110).
4. 哪些内容仍不明确？
The share of cancer deaths in which cachexia is the leading clinical feature varies by cancer type and is not quantified in the source reviewed (I-CAN-06).
5. 哪些研究支持该说法？
Partly: cachexia is common and can be a proximal cause of death (I-CAN-108); glucocorticoids contribute to muscle wasting (I-CAN-109, I-SRC-108).
6. 哪些研究与该说法相矛盾？
7. 对德国和欧洲而言情况如何？
Not region-specific; the same physiology and evidence apply.
8. 关于埃及的已知情况是什么？
Not region-specific; the same physiology and evidence apply.
9. 合理的实际结论是什么？
癌症患者出现非有意的体重下降时，需要及时获得医疗和营养方面的关注。
评估详情
- 证据确定性的依据
Moderate: an ESMO guideline (I-SRC-108), an international consensus (I-CAN-06) and a 2024 review (I-CAN-108) consistently describe cachexia as tumour-driven and improving with effective anticancer treatment; cause-of-death data show cancer as the underlying cause in most deaths (I-CAN-110). Quantitative data on the share of deaths dominated by cachexia are lacking.
- 来源质量
Machine transcript.
- 地区可推广性
High.
- 说法的地域范围
- 普遍性（生物学/医学）
- 最近审核
- 2026年10月26日 初步
科学证据详解
过度解读 – 确有真实的发现，但该说法从中引申出的结论超出了数据所能支持的范围（例如把关联当作因果、把动物数据套用到人身上、把小效应说成大效应）。
研究问题: In patients with advanced cancer, is death caused by wasting and hormonal (cortisol/cortisone) disturbance independently of the cancer, or are these part of the cancer process?
研究问题详解 (PECO)
- 人群
- Patients with advanced cancer
- 干预或暴露
- Cachexia; glucocorticoid (endogenous or therapeutic) exposure
- 对照
- Cancer progression and organ failure
- 地域范围
- universal biology
- 结局指标
- Cause of death
- Muscle wasting
- Response of cachexia to anticancer treatment
研究结果按作者报告呈现。我们的评估见下文。
哪些证据支持该说法？
Weight loss and survival in bowel and pancreatic cancer
Dunne RF et al.. J Cachexia Sarcopenia Muscle 2024 · PMID 39095951 · DOI 10.1002/jcsm.13510 系统综述已核查摘要新增Systematic review: cachexia/weight loss associated with poorer survival in colorectal and pancreatic cancer.
- 实际结果
- Significant association in 16 of 23 multivariate studies
- 方法学质量
- moderate (systematic review of observational studies; Pfizer-funded)
- 相关性
- direct for 'wasting matters'
- 局限
- Association may reflect cancer severity.
ESMO guideline on weight loss in cancer
Arends J et al. (ESMO Guidelines Committee). ESMO Open 2021 · PMID 34144781 · DOI 10.1016/j.esmoop.2021.100092 指南 / 立场声明已核查摘要新增ESMO guideline: prolonged corticosteroid therapy causes rapid muscle loss and worsens cachexia.
- 实际结果
- Corticosteroids limited to 2-3 weeks
- 方法学质量
- high (guideline)
- 相关性
- direct for the 'cortisone' kernel
- 局限
- Concerns medication, not a cause of death replacing cancer.
Why do people with cancer die?
Review: cachexia is a frequent proximal contributor to death and does not correlate with tumour volume.
- 实际结果
- Acute events may cause up to half of deaths; cachexia multifactorial
- 方法学质量
- moderate (narrative review)
- 相关性
- direct
- 局限
- Not systematic.
哪些证据不支持该说法？
ESMO guideline on weight loss in cancer
Arends J et al. (ESMO Guidelines Committee). ESMO Open 2021 · PMID 34144781 · DOI 10.1016/j.esmoop.2021.100092 指南 / 立场声明已核查摘要新增ESMO: effective anticancer treatment often improves cachexia; ineffective treatment aggravates it.
- 实际结果
- Guideline statement
- 方法学质量
- high
- 相关性
- direct: wasting is part of the cancer process
- 局限
- Expert-level evidence.
Cancer wasting is caused by the cancer itself
Fearon K et al.. Lancet Oncol 2011 · PMID 21296615 · DOI 10.1016/S1470-2045(10)70218-7 指南 / 立场声明已核查摘要International consensus defines cachexia as tumour-driven and not fully reversible by nutrition.
- 实际结果
- Consensus definition
- 方法学质量
- moderate
- 相关性
- direct
- 局限
- Consensus.
What cancer inpatients died of in an Indian hospital
Causes of inpatient cancer deaths in India.
- 实际结果
- Underlying cause cancer-related 83%; immediate: progression 57%, organ failure 21%, sepsis 15%
- 方法学质量
- low (single centre)
- 相关性
- direct
- 局限
- No cachexia category.
总体证据说明了什么？
基于上述研究的编辑评估——其本身并非研究结果。
哪种观点有更好的证据支持？
Wasting and hormonal-inflammatory changes are real mechanisms through which cancer kills; they are caused by the tumour and often improve when cancer treatment works. Separating them from 'dying of cancer' is a false dichotomy.
为什么有些研究权重更大
Guideline and consensus statements (I-SRC-108, I-CAN-06) and mechanistic reviews weigh more than single-centre data; animal data only explain mechanism.
因果关系是否已确立？ 是，已确立 Tumour-derived cytokines and signals cause cachexia (I-CAN-108, I-CAN-109); treating the tumour improves it (I-SRC-108).
仍存在的不确定性
Exact share of cancer deaths in which cachexia is the leading proximal cause is unknown.
合理的结论
The claim overinterprets a real phenomenon: patients do die with wasting, and glucocorticoids contribute, but this is part of dying from cancer.
为什么研究结果看起来互相矛盾？
这是否取决于国家？
- 一般生物学效应
- Universal human biology; applies in Egypt, Germany and elsewhere.
- 饮食习惯
- Not decisive for this claim.
- 食品原产地
- Not relevant.
- 污染物
- Not relevant.
- 本国生产条件
- Not relevant.
- 法律规则
- Not relevant.
- 实际监测数据
- Not applicable.
足以改变结论的地区差异没有可靠数据支持。
统计复核
- Recount of proportions – 57%/21%/15% of 474 deaths = about 270/100/71; cachexia not recorded separately. 已重新计算
总体证据的确定性（GRADE，简化版）
- 主要结局
- Cachexia as a cancer-driven process vs independent cause of death
- 起始等级
- 低（观察性研究）
- 降级理由
- imprecision (no quantitative cause-of-death data on cachexia)
- 升级理由
- consistency of mechanistic and guideline evidence
- biological gradient (improves with effective treatment)
- 结果
- 中
由单名审查者参照 GRADE 方法进行的简化评估；并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据，而非单项研究。
已核查的临床指南和官方声明
- ESMO: Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines (PMID 34144781) (2021) · 原始文献
Effective anticancer treatment often improves cachexia; nutritional support is recommended for patients receiving anticancer treatment; corticosteroids only for 2-3 weeks because prolonged use causes muscle loss and insulin resistance. - ESPEN: ESPEN guidelines on nutrition in cancer patients (I-INTA-09, PMID 27637832) (2017) · 原始文献
Screen all cancer patients for malnutrition and meet energy and protein needs, except at end of life (as recorded for I-INTA-09; abstract).
检索策略
本次审查的文献检索记录（检索式采用原数据库语法）。
| 数据库 | 日期 | 检索式 | 检索目标 | 命中数 | 纳入数 |
|---|---|---|---|---|---|
| Europe PMC | 2026年10月26日 | TITLE:"cancer cachexia" AND (TITLE:"ESMO" OR TITLE:"ASCO guideline") | 指南 | 7 | |
| Europe PMC | 2026年10月26日 | (autopsy OR "post-mortem" OR "immediate cause of death" OR "causes of death") AND ("cancer patients" OR "patients with cancer" OR "solid tumors") AND (cachexia OR infection OR "organ failure") | 双向 | 14713 | |
| Europe PMC | 2026年10月26日 | (glucocorticoid OR cortisol OR corticosterone) AND ("cancer cachexia") AND (muscle wasting) AND (TITLE:glucocorticoid OR TITLE:cortisol OR TITLE:corticosterone) | 支持性证据 | 13 | |
| Europe PMC | 2026年10月26日 | (Tayebat OR Tayibat OR Elawady OR "El-Awady diet" OR "Al-Awady") | 双向 | 377 | |
| PubMed | 2026年10月26日 | (cachexia[ti]) AND ("cause of death"[tiab] OR "causes of death"[tiab] OR mortality[ti]) | 支持性证据 | 93 | |
| PubMed | 2026年10月26日 | ("causes of death"[ti] OR "cause of death"[ti]) AND (cancer[ti] OR neoplasms[ti]) AND (autopsy[tiab] OR "death certificate"[tiab]) | 反对性证据 | 39 |
待解决的问题
Systematic autopsy data on proximal causes of cancer death.
核查深度如何？
6 项相关研究：0 项核查了全文（其中 0 项进行了结构化偏倚风险评估），6 项基于摘要核查，0 项仅核查了文献信息。 尚未进行由两名独立审查者完成的正式评估，也尚未进行独立的人类专家审核。
最近一次科学审核: 2026年10月26日
评定结论的变更历史
- 2026年10月25日 · 第 1 阶段 · 初始评估: 基本错误 (低)
- 2026年10月26日 · 第 4 阶段（系统证据审查） · 评定结论已更改: 基本错误 (低) → 基本错误 (中)
Certainty raised from low to moderate: the ESMO guideline (I-SRC-108), a 2024 review of causes of cancer death (I-CAN-108) and cause-of-death data (I-CAN-110) consistently show that cachexia is tumour-driven and responds to effective cancer treatment. The new evidence also supports a kernel (glucocorticoid signalling and prolonged corticosteroid therapy contribute to muscle loss), so the verdict stays MOSTLY_FALSE.
新来源: I-SRC-108 I-CAN-108 I-CAN-109 I-CAN-110 I-CAN-126
通俗解释
Diaa 医生说，癌症患者死于消瘦和可的松，而不是死于癌症。消瘦在晚期癌症中确实很常见，长期使用类固醇药物也会加重肌肉流失。但消瘦本身是由癌症引起的——癌症会改变食欲和新陈代谢——而且在癌症治疗有效时往往会改善。所以，消瘦是癌症致死的一种方式，而不是一个独立的死因。
与该说法相关的研究
支持该说法的研究 (0)
该组中没有研究。
与该说法相矛盾或限制该说法的研究 (3)
-
Cancer wasting is caused by the cancer itself
Fearon K et al.. Lancet Oncol 2011 · PMID 21296615 · DOI 10.1016/S1470-2045(10)70218-7指南 / 立场声明独立交叉核查已核查摘要Experts define cachexia as muscle loss driven by the tumour's effects on metabolism and appetite, not fully reversible by food.
Cachexia is part of the cancer process
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Define cachexia.
- 研究是如何开展的？
Delphi consensus.
- 研究了多少人、动物或样本？
Experts.
- 实际发现了什么？
Definition.
- 研究结果对日常生活意味着什么？
Weight loss in cancer needs medical attention.
- 该研究有哪些局限？
Consensus.
- 它对 Elawady 的具体说法说明了什么？
Contradicts 'not dying of cancer'.
- 研究结果是否适用于德国和欧洲？
High.
-
ESMO guideline on weight loss in cancer
Arends J et al. (ESMO Guidelines Committee). ESMO Open 2021 · PMID 34144781 · DOI 10.1016/j.esmoop.2021.100092指南 / 立场声明独立交叉核查已核查摘要Cancer patients on treatment should be screened for malnutrition and get at least 25-30 kcal per kg body weight per day.
Cachexia is cancer-driven and improves with effective anticancer treatment; prolonged corticosteroids worsen muscle loss (partial kernel)
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Guide cachexia care
- 研究是如何开展的？
Guideline
- 研究了多少人、动物或样本？
not applicable
- 实际发现了什么？
Screen and feed adequately; escalate nutrition when intake is low
- 观察到的效应有多大？
not applicable
- 研究结果对日常生活意味着什么？
Cancer patients need enough food, not fasting regimes
- 该研究有哪些局限？
Low evidence levels for some points
- 它对 Elawady 的具体说法说明了什么？
Contradicts fasting as treatment
- 研究结果是否适用于德国和欧洲？
High
-
What cancer inpatients died of in an Indian hospital
Doshi A et al.. Public Health Action 2026 · PMID 42830814 · DOI 10.5588/pha.26.0040队列研究独立交叉核查已核查摘要Most deaths were due to cancer progression (57%), organ failure (21%) or sepsis (15%).
Underlying cause of death cancer-related in 83%
该研究是否支持这一具体说法？ 否 · 方法学质量: 低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Describe causes of death.
- 研究是如何开展的？
Hospital record review.
- 研究了多少人、动物或样本？
474 deaths.
- 实际发现了什么？
Cancer progression dominant.
- 观察到的效应有多大？
57% immediate; 83% underlying.
- 研究结果对日常生活意味着什么？
People with cancer mostly die from the cancer and its complications.
- 该研究有哪些局限？
Single centre; no cachexia category.
- 它对 Elawady 的具体说法说明了什么？
Contradicts the claim.
- 研究结果是否适用于德国和欧洲？
Low-moderate.
- 从该研究中明确不能得出什么结论？
Role of cachexia.
该组中没有被标记为关键研究的研究。
结果不一或不明确的研究 (3)
-
Why do people with cancer die?
Boire A et al.. Nat Rev Cancer 2024 · PMID 38898221 · DOI 10.1038/s41568-024-00708-4叙述性综述独立交叉核查已核查摘要★ 关键研究Death in cancer usually results from several organ problems caused by the cancer, including wasting; tumour size alone does not explain it.
Cachexia is a real proximal mechanism, but it is caused by the cancer
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Review causes of death in cancer.
- 研究是如何开展的？
Narrative review.
- 研究了多少人、动物或样本？
Not applicable.
- 实际发现了什么？
Many interlinked causes, including cachexia.
- 观察到的效应有多大？
Acute events may cause up to half of deaths.
- 研究结果对日常生活意味着什么？
Wasting is one way cancer kills.
- 该研究有哪些局限？
Not systematic.
- 它对 Elawady 的具体说法说明了什么？
Partly right that tumour mass is not everything; wrong that cancer is not the cause.
- 研究结果是否适用于德国和欧洲？
High.
- 从该研究中明确不能得出什么结论？
Precise proportions.
-
Stress hormones help drive cancer wasting in mice
Braun TP et al.. FASEB J 2013 · PMID 23733748 · DOI 10.1096/fj.13-230375动物研究独立交叉核查已核查摘要Mice lacking glucocorticoid receptors in muscle lost 77% less muscle when they had tumours.
Glucocorticoid signalling mediates tumour-induced muscle wasting in mice
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Test role of glucocorticoids in cachexia.
- 研究是如何开展的？
Knockout mouse experiments.
- 研究了多少人、动物或样本？
Mice.
- 实际发现了什么？
Glucocorticoid signalling needed for much of the wasting.
- 观察到的效应有多大？
77% less atrophy.
- 研究结果对日常生活意味着什么？
Hormones are part of how cancer causes wasting.
- 该研究有哪些局限？
Mouse data.
- 它对 Elawady 的具体说法说明了什么？
Partly supports the hormonal idea, not the conclusion.
- 研究结果是否适用于德国和欧洲？
Low.
- 从该研究中明确不能得出什么结论？
Effects in humans.
-
Weight loss and survival in bowel and pancreatic cancer
Dunne RF et al.. J Cachexia Sarcopenia Muscle 2024 · PMID 39095951 · DOI 10.1002/jcsm.13510系统综述独立交叉核查已核查摘要In about two-thirds of studies, cancer patients with wasting or weight loss lived shorter.
Cachexia associated with poorer survival in ~2/3 of studies
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Link cachexia and survival.
- 研究是如何开展的？
Systematic review.
- 研究了多少人、动物或样本？
26 studies.
- 实际发现了什么？
Wasting linked to shorter survival.
- 观察到的效应有多大？
16 of 23 multivariate studies.
- 研究结果对日常生活意味着什么？
Weight loss in cancer needs attention.
- 该研究有哪些局限？
Observational; Pfizer funding.
- 它对 Elawady 的具体说法说明了什么？
Supports the kernel only.
- 研究结果是否适用于德国和欧洲？
High.
- 从该研究中明确不能得出什么结论？
That wasting rather than cancer kills.
该组中没有被标记为关键研究的研究。
地区背景
德国 / 欧盟
Not region-specific; the same physiology and evidence apply.
埃及
Not region-specific; the same physiology and evidence apply.
在我的国家适用什么？
一般科学评估
基本错误 消瘦和应激激素是癌症致死过程的一部分；它们由癌症引起，并不意味着患者死于癌症以外的原因。
该说法涉及生物学或医学关系。上述科学评估不论在哪个国家都适用；各国食品数据不会改变这一评估。
参考文献
- Definition and classification of cancer cachexia: an international consensus.. Fearon K et al.. Lancet Oncol 2011 · PMID 21296615 · DOI 10.1016/S1470-2045(10)70218-7
- Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines☆.. Arends J et al. (ESMO Guidelines Committee). ESMO Open 2021 · PMID 34144781 · DOI 10.1016/j.esmoop.2021.100092
- Why do cancer patients die? A decade of experience on trends, profile, causes, and timing of deaths in India.. Doshi A et al.. Public Health Action 2026 · PMID 42830814 · DOI 10.5588/pha.26.0040
- Why do patients with cancer die?. Boire A et al.. Nat Rev Cancer 2024 · PMID 38898221 · DOI 10.1038/s41568-024-00708-4
- Cancer- and endotoxin-induced cachexia require intact glucocorticoid signaling in skeletal muscle.. Braun TP et al.. FASEB J 2013 · PMID 23733748 · DOI 10.1096/fj.13-230375
- The mortality burden of cachexia or weight loss in patients with colorectal or pancreatic cancer: A systematic literature review.. Dunne RF et al.. J Cachexia Sarcopenia Muscle 2024 · PMID 39095951 · DOI 10.1002/jcsm.13510